A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...

CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, ...

Though CAR T cells have been effective against certain blood cancers, they have not been for solid tumors. Now, a new form of ...

A proof-of-concept study opens up an avenue for treating solid tumours that express low levels of a target antigen.

Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage immunotherapy company developing first-in-class logic-gated therapies for ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

What major challenge of traditional CAR-T does the in vivo alleviate/address? In addi | Dr Adrian Bot, Capstan Therapeutics, ...

Dr. Lakshmi Nayak, director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute, explained in an interview with ...

The first engineered cell therapy has come to the fight against solid tumors. Fox Chase Cancer Center has begun using Tecelra, an FDA-approved treatment for synovial sarcoma.

According to MarketsandMarkets™, the CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...